Business
Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study
Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study.
About this update from Cardax Inc
[{"type":"text","content":"\n \n Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that its \n astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated \n more than two and one-half times higher oral bioavailability than a \n leading microalgal astaxanthin product in a head-to-head monkey study. \n The study was conducted by top-tier contract research organizations and \n bioavailability was determined by measuring the plasma exposure of \n astaxanthin over four days following a single dose.\n \n \n CDX-085 is a patented pure ester of nature-identical astaxanthin and \n ASTX-1F is a proprietary formulation of nature-identical astaxanthin. \n The enhanced bioavailability of CDX-085 and ASTX-1F compared to \n microalgal astaxanthin should reduce the size/number of capsules or \n tablets required to achieve equivalent circulating levels of astaxanthin.\n \n \n Based on these results, the Company now intends to launch ASTX-1F as a \n first generation dietary supplement earlier in 2016 than previously \n expected, followed by CDX-085 as a second-generation dietary supplement \n and then OTC drug.\n \n \n “We are pleased to see the superior oral bioavailability of our product \n candidates in a scientifically rigorous study,” said Cardax CEO, David \n G. Watumull. “CDX-085 and ASTX-1F provide an unmatched combination of \n bioavailability, purity, intellectual property, and large scale \n manufacturing advantages.”\n \n \n About Cardax\n \n \n Cardax is a development stage life sciences company that devotes \n substantially all of its efforts to developing consumer health and \n pharmaceutical products that it believes will provide many of the \n anti-inflammatory benefits of steroids or NSAIDS by targeting many of \n the same inflammatory pathways and mediators, but with exceptional \n safety profiles. Cardax is preparing proprietary nature-identical \n products and related derivatives by total synthesis to provide scalable, \n pure, and economical therapies for diseases where inflammation and \n oxidative stress are strongly implicated, including, but not limited to, \n osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, \n diabetes, cardiovascular disease, hepatitis, cognitive decline, macular \n degeneration, and prostate disease. The initial primary focus of Cardax \n is its astaxanth...